The ALS Society of Canada presents ALS Clinical Trials Unboxed, a webinar series that provides an overview of an ongoing ALS clinical trial, followed by a Q&A period. For November, Dr. Stephan Miller, Director, Clinical Development at Ionis Pharmaceuticals and the project team leader for ulefnersen development for ALS, will present on the FUSION clinical trial. The FUSION trial is a randomized double-blind placebo-controlled trial to evaluate ulefnersen (ION363) as a potential therapy for FUS-ALS, a very rare form of ALS caused by mutations in the FUS gene. Ulefnersen, an antisense oligonucleotide, binds to the mutated RNA and causes it to be degraded. The trial has an 18-month placebo-controlled period followed by an open-label period in which all participants receive ulefnersen.
